Senti Biosciences Holdings, Inc. (SNTI) intrinsic value & 10-year financials
Senti Biosciences Holdings, Inc. (SNTI) has a Graham intrinsic value of $303.60 per share. At $0.22 on Oct 17, 2026, the stock trades 100% below that value. Over the last 6 fiscal years revenue shrank 68.7% a year to $22.0K, with an average return on invested capital of -314.8%.
- Graham intrinsic value
- $303.60
- Share price (Oct 17, 2026)
- $0.22
- Price vs Graham value
- 100% below
- Market cap
- $5.1M
- Revenue (FY2025)
- $22.0K
- Revenue growth (6-yr CAGR)
- -68.7%
- ROIC (10-yr avg)
- -314.8%
- Free cash flow (FY2025)
- -$43.6M
SNTI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $22.0K | -$61.4M | -$2.73 | -$43.6M | -312631.8% | -724.3% |
| FY2024 | $0 | -$52.8M | -$2.41 | -$41.4M | — | -172.5% |
| FY2023 | $2.0M | -$71.1M | -$0.32 | -$64.4M | -4687.9% | -84.0% |
| FY2022 | $3.3M | -$58.2M | -$0.45 | -$76.3M | -2149.4% | -100.4% |
| FY2021 | $2.3M | -$55.3M | -$0.42 | -$40.2M | -1765.4% | -492.9% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Senti Biosciences Holdings, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Senti Biosciences Holdings, Inc. has historically struggled to out-earn its cost of capital, averaging just -39.6% ROIC.
Senti Biosciences Holdings, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Senti Biosciences Holdings, Inc. is modeled at -68.7% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $303.60 per share.